TM
VIR icon

Torren Management’s Vir Biotechnology VIR Stock Holding History

Torren Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-87
Closed -$525 – 1442
2025
Q4 		$525 Buy
+87
New +$518 ﹤0.01% 1325

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Torren Management's VIR Position: Q1 2026 in Review

Torren Management sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 87 shares — an estimated $525 sold.

Torren Management first reported a position in VIR in Q4 2025 and held it in 1 quarter. The position peaked at $525 in Q4 2025. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Torren Management reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Torren Management sold 87 Vir Biotechnology shares in Q1 2026, an estimated $525.
  • Torren Management first reported a position in Vir Biotechnology in Q4 2025 and held it in 1 quarter.
  • Torren Management's Vir Biotechnology position peaked at $525 in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.